Free Trial
NASDAQ:CRNX

Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis

Crinetics Pharmaceuticals logo
$33.11 +0.72 (+2.22%)
Closing price 04/28/2025 04:00 PM Eastern
Extended Trading
$33.59 +0.48 (+1.45%)
As of 06:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)

Key Stats

Today's Range
$32.43
$33.60
50-Day Range
$25.56
$37.48
52-Week Range
$24.10
$62.53
Volume
605,996 shs
Average Volume
857,093 shs
Market Capitalization
$3.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$73.00
Consensus Rating
Moderate Buy

Company Overview

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

CRNX MarketRank™: 

Crinetics Pharmaceuticals scored higher than 73% of companies evaluated by MarketBeat, and ranked 158th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Crinetics Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Crinetics Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Crinetics Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.73) to ($4.11) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Crinetics Pharmaceuticals is -8.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Crinetics Pharmaceuticals is -8.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Crinetics Pharmaceuticals has a P/B Ratio of 4.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Crinetics Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    11.05% of the float of Crinetics Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Crinetics Pharmaceuticals has a short interest ratio ("days to cover") of 9.6.
  • Change versus previous month

    Short interest in Crinetics Pharmaceuticals has recently increased by 12.76%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Crinetics Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Crinetics Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.05% of the float of Crinetics Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Crinetics Pharmaceuticals has a short interest ratio ("days to cover") of 9.6.
  • Change versus previous month

    Short interest in Crinetics Pharmaceuticals has recently increased by 12.76%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Crinetics Pharmaceuticals has a news sentiment score of 1.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Crinetics Pharmaceuticals this week, compared to 7 articles on an average week.
  • Search Interest

    Only 1 people have searched for CRNX on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Crinetics Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,119,263.00 in company stock.

  • Percentage Held by Insiders

    Only 6.00% of the stock of Crinetics Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Crinetics Pharmaceuticals' insider trading history.
Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRNX Stock News Headlines

Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
See More Headlines

CRNX Stock Analysis - Frequently Asked Questions

Crinetics Pharmaceuticals' stock was trading at $51.13 at the start of the year. Since then, CRNX shares have decreased by 35.2% and is now trading at $33.11.
View the best growth stocks for 2025 here
.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) released its quarterly earnings data on Thursday, February, 27th. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04.
Read the conference call transcript
.

Crinetics Pharmaceuticals (CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

Top institutional shareholders of Crinetics Pharmaceuticals include SG Americas Securities LLC (0.56%), Rhumbline Advisers (0.14%), Hennion & Walsh Asset Management Inc. (0.04%) and Teacher Retirement System of Texas (0.02%). Insiders that own company stock include Richard Scott Struthers, Marc Wilson, Jeff E Knight, Dana Pizzuti, Stephen F Betz, Alan Seth Krasner, James Hassard, Matthew K Fust, Stephanie Okey and Coelho Rogerio Vivaldi.
View institutional ownership trends
.

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Crinetics Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), ServiceNow (NOW) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
2/27/2025
Today
4/28/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRNX
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$73.00
High Stock Price Target
$97.00
Low Stock Price Target
$54.00
Potential Upside/Downside
+120.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-214,530,000.00
Pretax Margin
-26,298.27%

Debt

Sales & Book Value

Annual Sales
$1.04 million
Price / Cash Flow
N/A
Book Value
$8.07 per share
Price / Book
4.10

Miscellaneous

Free Float
87,174,000
Market Cap
$3.08 billion
Optionable
Optionable
Beta
0.37
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:CRNX) was last updated on 4/29/2025 by MarketBeat.com Staff
From Our Partners